Cargando…
A novel kefir product (PFT) inhibits Ehrlich ascites carcinoma in mice via induction of apoptosis and immunomodulation*
BACKGROUND: The popularity of fermented foods such as kefir, kuniss, and tofu has been greatly increasing over the past several decades, and the ability of probiotic bacteria to exert anticancer effects has recently become the focus of research. While we have recently demonstrated the ability of the...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189677/ https://www.ncbi.nlm.nih.gov/pubmed/32345289 http://dx.doi.org/10.1186/s12906-020-02901-y |
_version_ | 1783527547801174016 |
---|---|
author | Badr El-Din, Nariman K. Shabana, Sameh M. Abdulmajeed, Bashar A. Ghoneum, Mamdooh |
author_facet | Badr El-Din, Nariman K. Shabana, Sameh M. Abdulmajeed, Bashar A. Ghoneum, Mamdooh |
author_sort | Badr El-Din, Nariman K. |
collection | PubMed |
description | BACKGROUND: The popularity of fermented foods such as kefir, kuniss, and tofu has been greatly increasing over the past several decades, and the ability of probiotic bacteria to exert anticancer effects has recently become the focus of research. While we have recently demonstrated the ability of the novel kefir product PFT (Probiotics Fermentation Technology) to exert anticancer effects in vitro, here we demonstrate its ability to inhibit Ehrlich ascites carcinoma (EAC) in mice. METHODS: Mice were inoculated intramuscularly with EAC cells to develop solid tumors. PFT was administered orally (2 g/kg/day) to mice 6 days/week, either 2 days before tumor cell inoculation or 9 days after inoculation to mice bearing solid tumors. Tumor growth, blood lymphocyte levels, cell cycle progression, apoptosis, apoptotic regulator expression, TNF-α expression, changes in mitochondrial membrane potential (MMP), PCNA, and CD4+ and CD8+ T cells in tumor cells were quantitatively evaluated by flow cytometry or RT-PCR. Further studies in vitro were carried out where EAC cells along with several other human cancer cell lines were cultured in the presence of PFT (0–5 mg/mL). Percent cell viability and IC(50) was estimated by MTT assay. RESULTS: Our data shows that PFT exerts the following: 1) inhibition of tumor incidence and tumor growth; 2) inhibition of cellular proliferation via a marked decrease in the expression of tumor marker PCNA; 3) arrest of the tumor cell cycle in the sub-G0/G1 phase, signifying apoptosis; 4) induction of apoptosis in cancer cells via a mitochondrial-dependent pathway as indicated by the up-regulation of p53 expression, increased Bax/Bcl-2 ratio, decrease in the polarization of MMP, and caspase-3 activation; and 5) immunomodulation with an increase in the number of infiltrating CD4(+) and CD8(+) T cells and an enhancement of TNF-α expression within the tumor. CONCLUSIONS: PFT reduces tumor incidence and tumor growth in mice with EAC by inducing apoptosis in EAC cells via the mitochondrial-dependent pathway, suppressing cancer cell proliferation, and stimulating the immune system. PFT may be a useful agent for cancer prevention. |
format | Online Article Text |
id | pubmed-7189677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71896772020-05-04 A novel kefir product (PFT) inhibits Ehrlich ascites carcinoma in mice via induction of apoptosis and immunomodulation* Badr El-Din, Nariman K. Shabana, Sameh M. Abdulmajeed, Bashar A. Ghoneum, Mamdooh BMC Complement Med Ther Research Article BACKGROUND: The popularity of fermented foods such as kefir, kuniss, and tofu has been greatly increasing over the past several decades, and the ability of probiotic bacteria to exert anticancer effects has recently become the focus of research. While we have recently demonstrated the ability of the novel kefir product PFT (Probiotics Fermentation Technology) to exert anticancer effects in vitro, here we demonstrate its ability to inhibit Ehrlich ascites carcinoma (EAC) in mice. METHODS: Mice were inoculated intramuscularly with EAC cells to develop solid tumors. PFT was administered orally (2 g/kg/day) to mice 6 days/week, either 2 days before tumor cell inoculation or 9 days after inoculation to mice bearing solid tumors. Tumor growth, blood lymphocyte levels, cell cycle progression, apoptosis, apoptotic regulator expression, TNF-α expression, changes in mitochondrial membrane potential (MMP), PCNA, and CD4+ and CD8+ T cells in tumor cells were quantitatively evaluated by flow cytometry or RT-PCR. Further studies in vitro were carried out where EAC cells along with several other human cancer cell lines were cultured in the presence of PFT (0–5 mg/mL). Percent cell viability and IC(50) was estimated by MTT assay. RESULTS: Our data shows that PFT exerts the following: 1) inhibition of tumor incidence and tumor growth; 2) inhibition of cellular proliferation via a marked decrease in the expression of tumor marker PCNA; 3) arrest of the tumor cell cycle in the sub-G0/G1 phase, signifying apoptosis; 4) induction of apoptosis in cancer cells via a mitochondrial-dependent pathway as indicated by the up-regulation of p53 expression, increased Bax/Bcl-2 ratio, decrease in the polarization of MMP, and caspase-3 activation; and 5) immunomodulation with an increase in the number of infiltrating CD4(+) and CD8(+) T cells and an enhancement of TNF-α expression within the tumor. CONCLUSIONS: PFT reduces tumor incidence and tumor growth in mice with EAC by inducing apoptosis in EAC cells via the mitochondrial-dependent pathway, suppressing cancer cell proliferation, and stimulating the immune system. PFT may be a useful agent for cancer prevention. BioMed Central 2020-04-28 /pmc/articles/PMC7189677/ /pubmed/32345289 http://dx.doi.org/10.1186/s12906-020-02901-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Badr El-Din, Nariman K. Shabana, Sameh M. Abdulmajeed, Bashar A. Ghoneum, Mamdooh A novel kefir product (PFT) inhibits Ehrlich ascites carcinoma in mice via induction of apoptosis and immunomodulation* |
title | A novel kefir product (PFT) inhibits Ehrlich ascites carcinoma in mice via induction of apoptosis and immunomodulation* |
title_full | A novel kefir product (PFT) inhibits Ehrlich ascites carcinoma in mice via induction of apoptosis and immunomodulation* |
title_fullStr | A novel kefir product (PFT) inhibits Ehrlich ascites carcinoma in mice via induction of apoptosis and immunomodulation* |
title_full_unstemmed | A novel kefir product (PFT) inhibits Ehrlich ascites carcinoma in mice via induction of apoptosis and immunomodulation* |
title_short | A novel kefir product (PFT) inhibits Ehrlich ascites carcinoma in mice via induction of apoptosis and immunomodulation* |
title_sort | novel kefir product (pft) inhibits ehrlich ascites carcinoma in mice via induction of apoptosis and immunomodulation* |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189677/ https://www.ncbi.nlm.nih.gov/pubmed/32345289 http://dx.doi.org/10.1186/s12906-020-02901-y |
work_keys_str_mv | AT badreldinnarimank anovelkefirproductpftinhibitsehrlichascitescarcinomainmiceviainductionofapoptosisandimmunomodulation AT shabanasamehm anovelkefirproductpftinhibitsehrlichascitescarcinomainmiceviainductionofapoptosisandimmunomodulation AT abdulmajeedbashara anovelkefirproductpftinhibitsehrlichascitescarcinomainmiceviainductionofapoptosisandimmunomodulation AT ghoneummamdooh anovelkefirproductpftinhibitsehrlichascitescarcinomainmiceviainductionofapoptosisandimmunomodulation AT badreldinnarimank novelkefirproductpftinhibitsehrlichascitescarcinomainmiceviainductionofapoptosisandimmunomodulation AT shabanasamehm novelkefirproductpftinhibitsehrlichascitescarcinomainmiceviainductionofapoptosisandimmunomodulation AT abdulmajeedbashara novelkefirproductpftinhibitsehrlichascitescarcinomainmiceviainductionofapoptosisandimmunomodulation AT ghoneummamdooh novelkefirproductpftinhibitsehrlichascitescarcinomainmiceviainductionofapoptosisandimmunomodulation |